Corporate Presentation

Obesity Survodutide Survodutide reduced blood pressure by up to 8.6 mmHg (systolic) and up to 4.8 mmHg (diastolic) at Week 46 Systolic blood pressure Diastolic blood pressure 2008 ZEALAND PHARMA Boehringer Ingelheim -2 -4 -6 -8 -10 -2.5 Adjusted mean (95% CI) absolute change from baseline (mmHg) -6.2 -12 -8.1 -8.7 -8.6 -14 Placebo Survodutide 0.6 mg QW Survodutide 2.4 mg QW Adjusted mean (95% CI) absolute change from baseline (mmHg) 0 -2 -4 -1.9 -3.3 -6 -4.4 -4.3 -4.8 -8 -10 -12 -14 Survodutide 3.6 mg QW Mean blood pressure at baseline across cohorts: 122.6-127.5 mmHg for systolic blood pressure; 80.5-82.4 mmHg for diastolic blood pressure. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries). Source: Figures adapted from Le Roux. Presentation at the 59th EASD Annual Meeting, October 2-6, 2023, Hamburg, Germany. Cl=confidence interval; QW-once-weekly. Survodutide 4.8 mg QW 28

View entire presentation